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A B S T R A C T
Limited information is available on health outcomes related to Zika virus infection acquired during child-
hood. Zika virus can cause severe central nervous system malformations in congenitally exposed fetuses
and neonates. In vitro studies show the capacity of Zika virus to infect neural progenitor cells, induce
central and peripheral neuronal cell deaths, and target different brain cells over the course of brain de-
velopment. Studies of postnatally infected mice and nonhuman primates have detected degradation of
neural cells and morphologic brain cell changes consistent with a broad neuroinflammatory response.
In addition, case reports of central nervous system disease in adults and in adolescents secondary to Zika
virus infection suggest that Zika virus may have a broader impact on neurological health beyond that
observed in congenitally exposed newborns. Long-term neurological complications have been observed
with other acquired flaviviral infections, with clinical symptoms manifesting for years after primary in-
fection. The extent to which postnatal Zika virus infection in humans negatively affects the central and
peripheral nervous systems and causes long-term neurological damage or cognitive effects is currently
unknown. To better understand the potential for neurological sequelae associated with acquired Zika virus
infection in children, we reviewed the biological, clinical, and epidemiologic literature and summarized
the evidence for this link. First, we review biological mechanisms for neurological manifestations of Zika
virus infection in experimental studies. Second, we review observational studies of congenital Zika virus
infection and case studies and surveillance reports of neurological sequelae of Zika virus infection in adults
and in children. Lastly, we discuss the challenges of conducting Zika virus-neurological sequela studies
and future directions for pediatric Zika virus research.
Background
In 2016, the World Health Organization designated the Zika virus
(ZIKV) epidemic as a Public Health Emergency of International
Concern because of the emerging association between micro-
cephaly and ZIKV infection during pregnancy.1 Although many
studies have evaluated the biochemical pathways for congenital ZIKV
infection and related severe neurodevelopmental fetal and neona-
tal outcomes, research on acquired ZIKV infection in children (i.e.,
ages one month to 18 years) is lacking. The few existing epidemio-
logic reports describe incidence rates of acquired ZIKV infection
among symptomatic children only and predominantly include prob-
able cases based on clinical signs and symptoms, rather than
laboratory-confirmed cases. Limited information is available on
health outcomes related to acquired ZIKV infection in children.
ZIKV, like other neurotropic viruses such as cytomegalovirus and
rubella, causes severe central nervous system (CNS) malforma-
tions in congenitally exposed fetuses and neonates. In vitro studies
of brain cells and organoids show that although ZIKV targets
forebrain-specific neural progenitor cells (NPCs), it has been shown
to induce both central and peripheral neuronal cell death and may
affect different brain cells over the course of brain development.2-5
Human brain development includes key processes of proliferation
and migration of glial progenitor cells that continue to differenti-
ate and mature throughout childhood and adolescence. These cells
are important for developing neural pathways and myelination.6 The
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neurotropic properties of ZIKV and its impact on developing neural
cells raise concerns about the potential neurological sequelae of post-
natal ZIKV infection.
Studies of postnatally infected mice and nonhuman primates have
detected degradation of neural cells and morphologic brain cell
changes consistent with a broad neuroinflammatory response.7-10
In addition, case reports of CNS disease in adults and adolescents
secondary to ZIKV infection suggest that ZIKV may have a broader
impact on neurological health beyond that observed in congeni-
tally exposed newborns.11 Long-term neurological complications have
been observed with other acquired flaviviral infections, such as West
Nile virus (WNV), with clinical symptoms manifesting for years after
primary infection.12-14 The extent to which postnatal ZIKV infec-
tion in humans can negatively affect the central and peripheral
nervous systems and cause long-term neurological damage or cog-
nitive effects is currently unknown.
To better understand the potential for neurological sequelae as-
sociated with ZIKV infection acquired during childhood, we reviewed
the biological, clinical, and epidemiologic literature and summa-
rized the evidence for this link. In this article, we first review
biological mechanisms for neurological manifestations associated
with ZIKV infection in experimental in vitro and in vivo studies.
Second, we review observational studies of congenital ZIKV infec-
tion and case studies and surveillance reports of neurological
sequelae secondary to ZIKV infection in adults and in children. Lastly,
we discuss the challenges of conducting ZIKV-neurological sequela
studies in children and future directions for pediatric ZIKV research.
Review of experimental studies
Neurotropism of ZIKV
In vitro studies
Evidence of ZIKV neurotropism is salient in the experimental lit-
erature. To identify the direct target cells of ZIKV, Tang et al. infected
human-induced pluripotent stem cells in various stages of corti-
cal neural development.15 Tang et al. found that ZIKV had high
efficiency for infecting forebrain-specific human NPCs and low ef-
ficiency for infecting human embryonic stem cells, human
pluripotent stem cells, and more differentiated cortical neurons. Tang
et al. further discovered that these forebrain-specific human NPCs
had attenuated growth and 30% reduced viability three days after
ZIKV infection.15 Souza et al. observed similarly deleterious effects
of ZIKV infection, that is, reduced NPC proliferation and cell death.16
Cugola et al. showed that human cortical progenitor cells, but not
fully differentiated neurons, continued to produce ZIKV RNA in the
culture supernatant after ZIKV exposure.3 Further, these investiga-
tors developed three-dimensional brain organoids derived from NPCs.
ZIKV-infected brain organoids developed morphologic abnormali-
ties and had higher rates of cell death compared with control
organoids. Notably, these in vitro studies support the affinity of ZIKV
for human NPCs, which may result in detrimental impact on de-
veloping brains.
Murine models
Since the 1970s, mouse models have provided important in-
sights into the neurotropic properties of ZIKV. The tropism of ZIKV
for immature neural cells was first demonstrated by Bell et al., who
performed intracerebral inoculation of ZIKV into newborn and five-
week-old mice. Bell et al. observed viral replication in neural and
astroglial cells and marked enlargement of astroglial cells.8 In another
study of newborn mice, Manangeeswaran et al. infected one-day-
old immunocompetent mice with two different strains of ZIKV and
found that ZIKV localizes to the CNS, resulting in degeneration of
Purkinje and granular cell layers of the mouse cerebellum and neu-
rological manifestations (e.g., ataxia, tremors, and seizures) two
weeks after infection.17 In another study of newborn mice, Fernandes
et al. reported that mice exposed to ZIKV via subcutaneous injec-
tion showed signs of CNS disease, including cortical lesions and
myelopathy, with moderate neuronal death.18 A related study by
Lazear et al. showed that five- to six-week-old transgenic mice
lacking innate antiviral immune responses sustained high viral loads
of ZIKV in the brain and the spinal cord after ZIKV challenge.19 These
mice also experienced related morbidity, including muscle weak-
ness and paralysis. These studies provide evidence of the tendency
of ZIKV to infect the developing CNS and cause cell death and related
neurological symptoms.
Other studies provide evidence of a less well-known but poten-
tially serious effect of ZIKV on NPCs in older brains. For example,
in a study of the impact of ZIKV on adult mouse brain neuropa-
thology, Li et al. found that ZIKV infection reduced NPC proliferation
and induced apoptotic cell death in the subgranular zone of the hip-
pocampus and the subventricular zone of the anterior forebrain of
infected mice.10 Because neurogenesis occurs in the same regions
of the brain in adult mice and in adult humans,6,20 results from these
murine studies reinforce the possible link between ZIKV infection
and neuropathologic alterations in the mature human brain.
Nonhuman primates
Evidence of the potential for persistent ZIKV infection and its
effect on the nervous system has been examined in nonhuman pri-
mates, who are natural hosts for the virus. ZIKV infection of adult
rhesus monkeys resulted in persistence of ZIKV in cerebrospinal fluid
(CSF) within the various body compartments examined for weeks
after viremia was cleared.21 Despite a robust humoral response de-
tected in blood, ZIKV-specific antibodies were not found in CSF,
suggesting a potential mechanism for viral persistence in the CSF.
Furthermore, the investigators observed upregulation of the mech-
anistic target of rapamycin (mTOR), a major regulator of key
processes of the developing and mature brain.22 Simultaneous
upregulation of mTOR and proinflammatory and antiapoptotic
pathways was suggested as part of the mechanism for persistent
ZIKV infection in the CNS. This viral persistence pathway may
be relevant to other ZIKV-related neurological sequelae (e.g., en-
cephalitis and Guillain-Barré syndrome [GBS]) in addition to
neurodevelopmental disorders. In another study, Hirsch et al. found
that infection of adult macaques with ZIKV resulted in persistence
of the virus in the peripheral nerves and the spinal cord for up to
five weeks post infection.23
The most compelling evidence to date of long-term neurologi-
cal sequelae associated with ZIKV infection comes from a study of
infant rhesus macaques (RMs) by Mavigner et al.24 They studied six
infant RMs who were postnatally inoculated with ZIKV PRVABC59
and two age-matched control RMs. In infected RMs, ZIKV per-
sisted in peripheral and CNS tissues for 14 to 15 days after infection
and histopathologic abnormalities were observed, including
Wallerian degeneration and astrogliosis. In the same study, mag-
netic resonance imaging (MRI) and functional MRI conducted in two
infected and two control RMs at ages three and six months showed
enlarged lateral ventricles, attenuated hippocampal development,
a reduction in white matter volume, and altered connectivity
between the amygdala, hippocampus, and orbital frontal cortex in
infected RMs compared with control RMs. The authors also re-
ported an alteration in the emotional behavior response to acute
stress at six months in infected RMs. Mavigner et al.’s study sug-
gests the potential for longer term functional and structural
neurological sequelae secondary to acquired ZIKV infection.
Flaviviruses and neurotropism
Animal and human studies have shown that, similar to ZIKV,
other flaviviruses, such as WNV and Japanese encephalitis, are
neurotropic and can persist for months in the CNS.25-27 In humans,
it is well established that WNV and Japanese encephalitis virus
can result in encephalitis and other severe consequences related
to neuroinflammation.28,29 Researchers have also observed
neuroinflammation after ZIKV infection in animal models,21,30 but
little is known about the neuroinflammatory properties of ZIKV in
humans. Although rare cases of ZIKV-related neuroinflammatory se-
quelae have been reported,31 more research is needed to understand
the mechanism by which ZIKV may result in encephalitis or men-
ingitis, particularly in children.
Review of epidemiologic research and case studies of ZIKV
infection
Congenital ZIKV exposure
ZIKV is the only flavivirus known to cause congenital brain ab-
normalities. During the Brazilian ZIKV outbreak, ZIKV was identified
by real-time reverse-transcriptase polymerase chain reaction (RT-
PCR) in amniotic fluid32 and in the fetal brain tissue of microcephalic
infants.33,34 ZIKV was also detected by RT-PCR in CSF and in brain
tissue in seven autopsies conducted on neonates with congenital
ZIKV infection who died within the first week of life. These autop-
sies revealed decreased brain weight with thinning parenchyma,
ventriculomegaly, cerebellar hypoplasia, and both macroscopic and
microscopic calcifications.35 Studies of human fetal and neonatal CNS
development following intrauterine exposure to ZIKV have identi-
fied some overlapping cognitive and sensorimotor disabilities often
observed in other congenital neurological syndromes. However, those
exposed to ZIKV also displayed some unique features leading to the
development of a clinical definition for congenital Zika syndrome,
that is, severe microcephaly with partially collapsed skull; malfor-
mation of cortical development; subcortical or basal ganglia
calcifications; chorioretinal atrophy and focal pigmentary retinal mot-
tling; congenital contractures not previously observed in fetal brain
disruption sequence; and marked early hypertonia and symptoms
of extrapyramidal involvement.36,37 It is unknown whether the neu-
robiological pathways that cause the morphologies seen in congenital
Zika syndrome also cause neurological effects in children who acquire
ZIKV infection postnatally.
Acquired ZIKV infection among children
Only a few ZIKV cases with neurological involvement have been
described among children. For example, travel-acquired ZIKV in-
fection appeared to trigger neuropsychiatric and cognitive symptoms
in a 16-year-old, although Epstein-Barr virus could not be ruled out.
Symptoms included poor processing speed, short-term memory loss,
and behavior suggestive of hypomania. ZIKV IgM antibodies were
detected in the adolescent’s CSF 15 days after symptom onset, and
single-photon emission computed tomography showed focal
moderate-to-severe hypoperfusion in the inferior left frontal region.38
Another case of ZIKV infection in an adolescent resulted in left-
sided hemiparesis, severe pain, and a bilateral loss of temperature
sensation. Although the adolescent’s brain MRI results were normal,
the spinal MRI result showed myelitis. In this case, Epstein-Barr virus
was ruled out and ZIKV RNA was detected in the CSF by RT-PCR.39
Epidemiologic studies of children and adults with acquired ZIKV
infection indicate that children appear to experience mild symp-
toms similar to those experienced by adults, most commonly fever,
maculopapular rash, arthralgia, or nonpurulent conjunctivitis. Few
studies have reported age-specific ZIKV prevalence and incidence
rates. Among children in Colombia, the highest rates were re-
ported among children ages 15 to 18 years.40 In Micronesia, children
had lower reported rates compared with adults,41 whereas in Puerto
Rico, incidence among nonpregnant persons was highest among the
10- to 19-year-old age group.42 Thirty-three percent of individuals
enrolled in the Sentinel Enhanced Dengue Surveillance System in
Puerto Rico were ZIKV infected, of which 26% were children.43 These
studies include only symptomatic children reported to the countries’
surveillance systems and, except for Puerto Rico, are mainly based
on probable rather than laboratory-confirmed case reports. Studies
of children with asymptomatic ZIKV have not been published.
No studies have systematically evaluated risk of neurological se-
quelae associated with ZIKV acquisition during childhood, and only
one study evaluated neurological sequelae secondary to ZIKV in-
fection in children. Tolosa et al. reported detailed demographic,
geographic, health outcome, and ZIKV incidence data for children
throughout Colombia.40 Of the 18,576 children ages 1 month to 18
years with suspected ZIKA infection identified through Colom-
bia’s National Health Surveillance System between August 2015 and
May 2016, only 1655 (8.9%) were tested for ZIKV infection by RT-
PCR, 72.9% of whom were ZIKV positive. At the time of the report,
96 (0.5%) of the 18,576 children with suspected ZIKV had an asso-
ciated neurological diagnosis related to ZIKV infection, 29% of whom
were aged one month to six years. However, only 25 of the 96 chil-
dren were tested for ZIKV by RT-PCR, and only 12 (48%) of those
were positive. Of the 96 children with suspected ZIKV with neu-
rological complications, 40 had GBS, 24 had polyneuropathy, and
20 had encephalitis. The conditions observed among the 12 chil-
dren with laboratory-confirmed ZIKV infection were not specifically
reported. Tolosa et al.’s study also reported that 631 (3.4%) of the
children with suspected ZIKV were hospitalized, but reasons for hos-
pitalization were not reported. One child with laboratory-confirmed
ZIKV infection died because of complications of GBS, secondary to
ZIKV infection.
Acquired ZIKV infection among adults
Although the epidemiologic and clinical research on acquired ZIKV
infection has focused mainly on adults, such studies can elucidate
the possible range of severe central and peripheral nervous system
manifestations that may present with acquired ZIKV infection in
childhood. Several studies found an increased incidence of GBS
during the ZIKV epidemic, and recent GBS case series have found
evidence of ZIKV infection in many of these patients.31,44-49 Other
neurological manifestations in adults have included myelitis, en-
cephalitis, meningoencephalitis, chronic and acute inflammatory
demyelinating polyneuropathy, and transient hearing loss.31,50-54 Acute
neuromuscular disease has been observed among patients with ZIKV-
related encephalitis and among patients with ZIKV-related GBS.31,51
MRI results of adult ZIKV-infected patients have depicted cortical
edema, changes in the lenticular nucleus, and brain abnormalities
consistent with cerebral vasculitis, which ultimately resolved.51,54
Although fully formed adult brains may be affected by and recover
from ZIKV infection differently from children’s brains, the fact that
acquired ZIKV infection can cause an inflammatory response in the
brain raises concern about the possible impact of ZIKV infection on
the developing nervous system.
Discussion
Although many studies have investigated the risks of ZIKV during
pregnancy and onset of GBS after ZIKV infection, few studies have
evaluated ZIKV symptoms and associated health outcomes among
children with acquired ZIKV infection. Symptoms appear to be similar
among children and adults, but experimental studies illustrate the
ability of ZIKV to spread through brain tissues, persist in CSF fluid,
and disrupt important brain cell development when exposure occurs
outside the womb. This body of evidence raises questions about the
possibility of undetected neural cell damage among children with
acquired ZIKV infection and related subtle neurological impair-
ment that may not be discovered unless scientists take a closer look.
Emerging evidence indicates that ZIKV is capable of disrupting
the function of NPCs and causing neural stem cell death. NPCs dif-
ferentiate into mature brain cells, and although much of this occurs
during fetal brain development, the process of differentiation and
maturation continues throughout childhood and into adulthood.6
Furthermore, the areas of the brain that house these vulnerable NPCs
are the hippocampus and the anterior forebrain, responsible for
learning, memory, and behavior. Although many of the symptoms
of ZIKV-associated neurological conditions (e.g., meningitis, en-
cephalitis, and GBS) have known trajectories, the potential
neurodevelopmental impact of more subtle damage is unknown and
may ultimately have a broader public health impact.
Information is limited about disease characteristics (e.g., infec-
tion prevalence, incidence, severity, and transmission) and health
outcomes among children with postnatally acquired ZIKV infec-
tion. Transmission risk specific to children has not been studied. ZIKV
can be found in breast milk,55 but it is unknown whether the pres-
ence of virus in breast milk can result in mother-to-infant
transmission. More research is needed to understand the risk of ZIKV
acquisition among children, particularly if the epidemiologic evi-
dence reveals poor health outcomes associated with pediatric ZIKV
infection. Better surveillance is needed to quantify the incidence and
attack rates of ZIKV infection among children and to identify po-
tential downstream neurological sequelae; geolocation of these cases
is needed to anticipate future outbreaks. Children may be exposed
to ZIKV in different settings compared with adults (e.g., in day care
and schools), making it important to understand how and when case
clustering occurs among children, ZIKV virulence in children, and
the potential for herd immunity. Other factors that may increase
risk of adverse outcomes among children have also not been studied
in the context of ZIKV. For example, are children with existing neu-
rological conditions or autoimmune disorders at risk of worsening
clinical outcomes? Are there sensitive periods of neurodevelopment
where ZIKV may have its worst impact? Additional studies are
needed to evaluate both subclinical neurological damage (e.g., brain
lesions and cell death) and neuropsychological outcomes (e.g., ex-
ecutive functioning, sensorimotor functioning, and memory) among
healthy children and those with health vulnerabilities.
To address these research gaps, scientists, health-care provid-
ers, and public health practitioners must improve dissemination of
ZIKV-related public health information to the public, develop non-
invasive and accurate assays, and increase capacity building for
neurological and neuropsychological evaluation. It is increasingly
important to communicate ZIKV transmission risks and symp-
toms to health-care practitioners and the general public and to
encourage families to bring their asymptomatic children in for ZIKV
testing. We also recommend that children be included in epide-
miologic ZIKV studies, when possible, and that results of those
studies be stratified by age, sex, and presence of symptoms to permit
a better understanding of the distribution of infections, clinical char-
acteristics, and health sequelae among children. Development of
more specific and sensitive assays is currently under way. A non-
invasive urine or saliva collection procedure may facilitate testing
of infants and young children in routine surveillance and re-
search. In some children, ZIKV RNA can be detected in saliva in the
absence of RNA detection in blood.56 ZIKV RNA has been detected
in urine at higher levels and for longer durations compared with
serum, making urine an excellent specimen type for ZIKV testing,
particularly in the acute period of infection.57,58 Further develop-
ment of assays for these fluid types is under way.59-61
Many of the well-established and normed neurocognitive, psy-
chological, and developmental tests for this type of research were
developed in the United States and have not been validated in low-
resource, Spanish- and Portuguese-speaking settings. Validation of
existing neuropsychological assessment instruments in regions with
ZIKV transmission is needed to evaluate the cultural appropriate-
ness of vocabulary and concepts and to develop norms for diverse
contexts. In this regard, instruments should be selected for use and
validation based on their ability to uncover focal and generalized
dysfunctions; age appropriateness with tasks across the life span
if possible; availability of age-based normative data; strong psy-
chometric properties; ease of administration by nonpsychologists;
and, if possible, availability or ease of translation into Spanish and
Portuguese and other local (e.g., Quechua and Creole) dialects. In-
creased capacity building among health-care and school-based
providers to administer these instruments is necessary to encour-
age their use in research and to ensure standardized implementation
and common data elements across studies. In the context of ZIKV,
robust neuropsychological assessment training and implementa-
tion will facilitate evaluation of the full impact of ZIKV on children’s
neurodevelopment in regions with ZIKV transmission.
Conclusion
Given the large public health impact of ZIKV, it is critically im-
portant to understand how this infection will impact neurobehavioral
outcomes and neurodevelopmental trajectories for children at risk
of ZIKV infection. Although experimental studies provide key in-
sights into the biological mechanism of ZIKV infection, longitudinal
epidemiologic studies in children with acquired infection are needed
to better understand how ZIKV infection may impair short- and long-
term neurodevelopment and to evaluate the persistence of
neurological sequelae over time. This information will help deter-
mine intervention strategies to address the care and follow-up of
ZIKV-infected children.
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